Clinical Trial Update: Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial evaluates the combination of ivosidenib, durvalumab, and gemcitabine/cisplatin as first-line therapy for locally advanced or metastatic chol…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Durvalumab (Imfinzi) (durvalumab)
• Gemcitabine (Gemzar) (gemcitabine)
• Ivosidenib (Tibsovo) (ivosidenib)

Snippet

Sponsor: Institut de Recherches Internationales Servier | Conditions: Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation | Phase 1, Phase 2 | Status: RECRUITING